WO2009009528A2 - Diabetes insulin sensitivity, carbohydrate ratio, correction factors data self-monitoring product - Google Patents
Diabetes insulin sensitivity, carbohydrate ratio, correction factors data self-monitoring product Download PDFInfo
- Publication number
- WO2009009528A2 WO2009009528A2 PCT/US2008/069416 US2008069416W WO2009009528A2 WO 2009009528 A2 WO2009009528 A2 WO 2009009528A2 US 2008069416 W US2008069416 W US 2008069416W WO 2009009528 A2 WO2009009528 A2 WO 2009009528A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- score
- glucose
- blood glucose
- weight
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Definitions
- Diabetes is a complex of disorders, characterized by a common final element of hyperglycemia, that arise from, and are determined in their progress by mechanisms acting at all levels of bio-system organization - from molecular to human behavior. Diabetes mellitus has two major types: Type 1 (TlDM) caused by autoimmune destruction of insulin producing pancreatic beta-cells, and Type 2 (T2DM), caused by defective insulin action (insulin resistance) combined with progressive loss of insulin secretion. Over 20 million people are currently afflicted by diabetes in the US, with epidemic increases now occurring.
- TlDM Type 1
- T2DM Type 2
- Insulin sensitivity refers to the sensitivity of glucose clearance to plasma insulin variations.
- SI DF
- SI BQ
- SI an index of insulin sensitivity, which is derived using the DeFronzo method, unless otherwise specified.
- Assessment of insulin sensitivity can be done in several ways, but two major protocols have been favored in the past 3 decades: the hyperinsulemic euglycemic clamp and the glucose tolerance test (intravenous or oral, IVGTT or OGTT).
- the first method is based on the work by DeFronzo et al. (18), which estimates SI as the ratio of the average glucose injection during the last 30 minutes of the protocol divided by the plasma insulin concentration (constant because clamped). It is widely used, referred to in more than 2,200 publications, and generally accepted as a gold standard.
- the second method uses the glucose-insulin dynamics mathematically characterized by Bergman and Cobelli 's now classic Minimal Model (4) and by a number of subsequent studies (3,6,7,11,31). A recent count showed that the Minimal Model had been used in >600 publications (12). A newer c-peptide minimal model allowed for a more precise evaluation of ⁇ -cell function (34, 35, 36). Further research showed that oral glucose tolerance test could be used as well (9, 10, 13, 14, 15). The oral models have been extensively validated in the nondiabetic population, but more work is needed to assess their domain of validity in the diabetes, albeit first results are promising (1).
- the Minimal Model (2) allows estimating SI( BQ an d insulin action (X) from oral or intravenous tests. Usually the model is numerically identified by nonlinear least squares or maximum likelihood.
- Disposition index In pre-diabetes, insulin resistance is compensated by increased insulin secretion from the ⁇ -cell. Until this compensation fails, near-normal glucose tolerance is maintained. If diminished, ⁇ - cell responsivity could lead to the development of T2DM. It was shown that in health the relationship between insulin sensitivity and ⁇ -cell function, as estimated from the Minimal Model, is hyperbolic, i.e. insulin sensitivity X ⁇ -cell function equals a constant (5, 25). Figure 1 represents this hyperbolic relationship, which indicates normal glucose tolerance (sold line in Figure 1). For example, state 1 represents normal insulin sensitivity and normal ⁇ -cell response, while in state 2 insulin resistance is increased, but the ⁇ -cells compensate with increased output.
- DI Disposition index
- insulin sensitivity (and therefore DI) is not fixed within a person - these indices change over time and with various modes of treatment.
- the SI (defined by either formula) is particularly vulnerable to the effects of physical activity, which can increase insulin sensitivity for hours after exercise (30,33,38).
- muscle contraction increases total blood flow to muscle (37) and recruits capillaries (17), thereby increasing the uptake of glucose.
- insulin sensitivity has natural circadian cycles, e.g. insulin resistance appears to be highest in morning, particularly in T2DM, (8,28).
- Insulin boluses are traditionally calculated in two phases: First, the amount of insulin is computed that is needed by a person to compensate for the carbohydrate content of an incoming meal. This is done by estimating the amount of carbohydrates to be ingested and multiplying by each person's insulin/carbohydrate ratio. Second, the distance between actual blood glucose (BG) concentration and individual target level is calculated and the amount of insulin to reach target the target is computed. This is done by multiplying the (BG - target) difference by individual insulin correction factor.
- BG blood glucose
- SI insulin sensitivity
- An aspect of the methods, systems, and computer program products presented in this invention may use routine SMBG data, combined with easily accessible personal parameters.
- the method and system assessing individual SI is validated by comparison of its results against reference hospital-based assessment of SI computed using DeFronzo's method and data from euglycemic clamp performed on 30 patients with TlDM.
- An aspect of various embodiments of the present invention provides, but not limited thereto, a method, computer method, system, computer system, computer program product and algorithm for evaluation of insulin sensitivity (SI) from routine self- monitoring blood glucose (SMBG) data. While SI is one of the most important parameters of diabetes, an aspect of this invention also includes methods applying SI to deriving two, person-specific, parameters of diabetes management: (i) carbohydrate ratio used to estimate the amount of insulin needed to compensate for upcoming meal, and (ii) correction factor used to adjust insulin amount so a target glucose level can be reached.
- SI insulin sensitivity
- SMBG routine self- monitoring blood glucose
- the related methods and systems may use routine SMBG data collected over a period of 2-6 weeks (or duration or frequency as desired or required) and is based on our previously developed theory of risk analysis of blood glucose data, in particular on a previously introduced glucose variability measure, the Average Daily Risk Range (ADRR), see PCT International Application No. PCT/US2007/000370, filed January 5, 2007, entitled “Method, System and Computer Program Product for Evaluation of Blood Glucose Variability in Diabetes from Self-Monitoring Data;” of which is hereby incorporated by reference herein in its entirety.
- ADRR Average Daily Risk Range
- SMBG is defined as episodic non-automated determination (typically 3-5 times per day) of blood glucose at diabetic patients' natural environment.
- aspects of various embodiments of the present invention may pertain directly to: ⁇ Enhancement of existing SMBG devices by introducing a data interpretation component capable of evaluating insulin sensitivity (or insulin resistance, which is a clinically acceptable term, particularly in Type 2 diabetes). Because insulin sensitivity is difficult to measure, and its assessment is critical to optimizing the treatment of diabetes, this feature can be stand-alone, or combined with the features described below;
- Enhancement by the same features of software that retrieves SMBG data - such software is produced by virtually every manufacturer of home BG monitoring devices and is customarily used by patients and health care providers for interpretation of SMBG data.
- the software can reside on patients personal computers, or be used via Internet portal;
- a specific application may be the routine assessment of insulin sensitivity (or insulin resistance) in health-care setting. Such an assessment would include basic measurements (weight, height, insulin dosing) combined with SMBG from a person's memory meter.
- the invention provides a computerized method, computer program product and system using running estimates of the SI of a person based on SMBG data collected over a predetermined duration to evaluate changes in insulin requirements.
- An aspect of an embodiment of the present invention provides a method for evaluation of insulin sensitivity (SI) of a user from routine self-monitoring blood glucose (SMBG) data.
- the method comprising: applying the SI to derive at least one component of diabetes management.
- One of the components may comprise: a carbohydrate ratio used to estimate the amount of insulin needed to compensate for upcoming meal, a correction factor used to adjust insulin amount so a target glucose level can be reached, or both the carbohydrate ratio and the correction factor.
- An aspect of an embodiment of the present invention provides a system for evaluating insulin sensitivity (SI) of a user from routine self-monitoring blood glucose (SMBG) data.
- the system may comprise an acquisition module acquiring plurality of SMBG data points; and a processor.
- the processor may be programmed to: apply the SI to derive at least one component of diabetes management.
- At least one of the components may comprise: a carbohydrate ratio used to estimate the amount of insulin needed to compensate for upcoming meal, a correction factor used to adjust insulin amount so a target glucose level can be reached, or both of the carbohydrate ratio and correction factor.
- An aspect of an embodiment of the present invention provides a computer program product comprising a computer useable medium having computer program logic for enabling at least one processor in a computer system to evaluate insulin sensitivity (SI) of a user from routine self-monitoring blood glucose (SMBG) data.
- the computer program logic may comprise: applying the SI to derive at least one component of diabetes management.
- At least one of the components may comprise: a carbohydrate ratio used to estimate the amount of insulin needed to compensate for upcoming meal, a correction factor used to adjust insulin amount so a target glucose level can be reached, or both of the carbohydrate ratio and the correction factor.
- Figure 1 graphically illustrates the hyperbolic relationship between insulin sensitivity and ⁇ -cell responsivity - disposition index.
- Figure 2 graphically illustrates the dynamics of appearance and clearance of glucose during a meal + insulin bolus
- Figure 3 graphically illustrates the relationship between SI and its estimates SIl and SI2;
- Figure 4 graphically illustrates the relationship between carbohydrate ratio computed from SIl and the "450 rule" - an accepted method for computing carbohydrate ratio
- Figure 5 graphically illustrates the relationship between correction factor computed from SIl and the "1800 rule" - an accepted method for computing correction factors.
- Figure 6 provides a simplified flowchart or schematic block diagram of an aspect of an exemplary embodiment of the present invention method, system and computer program product for evaluating or determining a user's insulin sensitivity (SI).
- SI insulin sensitivity
- Figure 7 Functional block diagram for a computer system for implementation of embodiments of the present invention
- Figure 8 Schematic block diagram for an alternative variation of an embodiment of the present invention relating processors, communications links, and systems;
- Figure 9 Schematic block diagram for another alternative variation of an embodiment of the present invention relating processors, communications links, and systems;
- Figure 10 Schematic block diagram for a third alternative variation of an embodiment of the present invention relating processors, communications links, and systems.
- An aspect of an embodiment of the present invention is, but not limited thereto, the estimate of individual insulin sensitivity (SI) derived from personal parameters and SMBG data.
- SI insulin sensitivity
- An aspect of the present invention method or system is the understanding that steady state glucose concentration is controlled via changes in insulin basal rate, while boluses are used to compensate for glycemic events (e.g. meals).
- Data and data pre-processing is the understanding that steady state glucose concentration is controlled via changes in insulin basal rate, while boluses are used to compensate for glycemic events (e.g. meals).
- a first step, for example, of computation of insulin sensitivity estimate includes the retrieval of all SMBG data points collected during the last 2-6 weeks of monitoring (or duration as desired or required). These data are then pre-processed as previously described to compute the average daily risk range (ADRR) for a person for this period in time (see U.S. Serial No. 11/943,226, filed November 20, 2007, entitled “Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes," and recently published (27) algorithm, of which are hereby incorporated by reference herein in their entirety).
- ADRR average daily risk range
- X 1 1 , X 2 1 , ... X n be a series of n 1 SMBG readings taken on Day 1;
- a second step, for example, of data collection includes measurement of the following personal parameters: 1. Age and duration of diabetes (these are entered only once); 2. Weight and height to compute body mass index (BMI), recomputed every few months;
- SI insulin sensitivity
- SCORE therefore can range between 0 and 4 for each person, is generally slow-changing, and can change with a person's insulin dose, BMI, or with Age/Duration of diabetes.
- the estimate of SI is then given by a linear combination of ADRR and SCORE, i.e. by the formula:
- SI4 0.645653*ADRR + 5.477073*SCORE .
- the carbohydrate ratio is used, as previously described, to estimate the amount of insulin needed by a person with diabetes to compensate for ingested glucose.
- optimal diabetes control would mean matching the total amount of glucose entering the system after a meal to the total amount of glucose cleared due to the pre-meal insulin bolus. This is equivalent to equating the integrals of the rate of appearance and the clearance.
- TIDGC total insulin dependent glucose clearance
- Ib stands for basal insulin (created by the basal rate alone) and Si stands for insulin sensitivity as defined above.
- N is a time constant of insulin diffusion and V a volume of insulin diffusion (neither are not necessarily used in further computation)
- TIDGC s bolus[mU] 1 CL
- CL is a subject-specific parameter dependent on insulin clearance and insulin diffusion volume. CL is approximated using field-measurable subject characteristics as follows:
- BSA 0.20247. Height[mf 125 W [kg] 0425 where BSA stands for body surface area.
- TGI weight [kg]
- TGI TIDGC 1 000 meal _ ⁇ bolusjmU] weight CL bolus[U] CL meal[g] S j .weight[kg]
- the correction factor represents a change in insulin for the purpose of clearing certain amount of glucose from the bloodstream, i.e. for the purpose of bringing BG from its current level to a target level. Therefore the problem can be summarized as equating an additional integral insulin dependent glucose clearance to the observed difference between plasma glucose concentration and targeted glucose concentration:
- the adjustment coefficients for a number of insulin types and mixtures are given in (20) and range from 0.75 for fast- acting insulin (e.g. regular or Lispro) to 0.3-0.4 for slow-acting insulin (e.g. NPH or lente). For insulin pump users, a fixed adjustment coefficient of 0.75 should be generally acceptable.
- BG was sampled every 5 minutes (Beckman glucose analyzer) to measure SI. The same subjects also performed routine SMBG for 30 days, 4-5 times/ day. The ADRR was computed from these SMBG as described above. Demographic and other personal parameters were collected as well.
- Table 1 shows the correlation of the clamp-estimated SI with demographic and SMBG-derived parameters. All correlations are in the expected direction, and some notable are in bold.
- Figure 3 presents the relationship between the reference SI (x-axis) and its estimates SIl and SI2 computed by the first two formulas presented above.
- FIG. 6 provides a simplified flowchart or schematic block diagram of an aspect of an exemplary embodiment of the present invention method, system and computer program product for evaluating or determining a user's insulin sensitivity (SI).
- An initial step or module may include acquiring SMBG readings from a predetermined period 670.
- Another step or module may include computing an estimate of insulin sensitivity (SI) from the SMBG readings 675.
- Another step or module may include using the estimate of SI to compute individualized carbohydrate ratio 680.
- another step or module may include using the estimate of SI to compute individualized correction factor 685.
- the computation of the two components of an insulin dose calculator, carbohydrate ratio and correction factor uses this estimate, which allows the tailoring of carbohydrate ratio and correction factor to the present state of the person.
- Figure 7 is a functional block diagram for a computer system 700 for implementation of an exemplary embodiment or portion of an embodiment of present invention.
- a method or system of an embodiment of the present invention may be implemented using hardware, software or a combination thereof and may be implemented in one or more computer systems or other processing systems, such as personal digit assistants (PDAs) equipped with adequate memory and processing capabilities, or directly into blood glucose self-monitoring devices (e.g., SMBG memory meters) equipped with adequate memory and processing capabilities.
- PDAs personal digit assistants
- SMBG memory meters blood glucose self-monitoring devices
- the invention was implemented in software running on a general purpose computer 700 as illustrated in Figure 7.
- the computer system 700 may includes one or more processors, such as processor 704.
- the Processor 704 is connected to a communication infrastructure 706 (e.g., a communications bus, cross-over bar, or network).
- the computer system 700 may include a display interface 702 that forwards graphics, text, and/or other data from the communication infrastructure 706 (or from a frame buffer not shown) for display on the display unit 730.
- Display unit 830 may be digital and/or analog.
- the computer system 700 may also include a main memory 708, preferably random access memory (RAM), and may also include a secondary memory 710.
- the secondary memory 710 may include, for example, a hard disk drive 712 and/or a removable storage drive 714, representing a floppy disk drive, a magnetic tape drive, an optical disk drive, a flash memory, etc.
- the removable storage drive 714 reads from and/or writes to a removable storage unit 718 in a well known manner.
- Removable storage unit 718 represents a floppy disk, magnetic tape, optical disk, etc. which is read by and written to by removable storage drive 714.
- the removable storage unit 718 includes a computer usable storage medium having stored therein computer software and/or data.
- secondary memory 710 may include other means for allowing computer programs or other instructions to be loaded into computer system 700.
- Such means may include, for example, a removable storage unit 722 and an interface 720.
- removable storage units/interfaces include a program cartridge and cartridge interface (such as that found in video game devices), a removable memory chip (such as a ROM, PROM, EPROM or EEPROM) and associated socket, and other removable storage units 722 and interfaces 720 which allow software and data to be transferred from the removable storage unit 722 to computer system 700.
- the computer system 700 may also include a communications interface 724.
- Communications interface 724 allows software and data to be transferred between computer system 700 and external devices.
- Examples of communications interface 724 may include a modem, a network interface (such as an Ethernet card), a communications port (e.g., serial or parallel, etc.), a PCMCIA slot and card, a modem, etc.
- Software and data transferred via communications interface 724 are in the form of signals 728 which may be electronic, electromagnetic, optical or other signals capable of being received by communications interface 724.
- Signals 728 are provided to communications interface 724 via a communications path (i.e., channel) 726.
- Channel 726 (or any other communication means or channel disclosed herein) carries signals 728 and may be implemented using wire or cable, fiber optics, blue tooth, a phone line, a cellular phone link, an RF link, an infrared link, wireless link or connection and other communications channels.
- computer program medium and “computer usable medium” are used to generally refer to media or medium such as various software, firmware, disks, drives, removable storage drive 714, a hard disk installed in hard disk drive 712, and signals 728.
- These computer program products are means for providing software to computer system 700.
- the computer program product may comprise a computer useable medium having computer program logic thereon.
- the invention includes such computer program products.
- the "computer program product” and “computer useable medium” may be any computer readable medium having computer logic thereon.
- Computer programs are may be stored in main memory 708 and/or secondary memory 710. Computer programs may also be received via communications interface 724. Such computer programs, when executed, enable computer system 700 to perform the features of the present invention as discussed herein. In particular, the computer programs, when executed, enable processor 704 to perform the functions of the present invention. Accordingly, such computer programs represent controllers of computer system 700.
- the software may be stored in a computer program product and loaded into computer system 700 using removable storage drive 714, hard drive 712 or communications interface 724.
- the control logic when executed by the processor 704, causes the processor 704 to perform the functions of the invention as described herein.
- the invention is implemented primarily in hardware using, for example, hardware components such as application specific integrated circuits (ASICs).
- ASICs application specific integrated circuits
- the invention is implemented using a combination of both hardware and software.
- the methods described above may be implemented in SPSS control language or C + + programming language, but could be implemented in other various programs, computer simulation and computer- aided design, computer simulation environment, MATLAB, or any other software platform or program, windows interface or operating system (or other operating system) or other programs known or available to those skilled in the art.
- FIGS. 8-10 show block diagrammatic representations of alternative embodiments of the invention.
- a block diagrammatic representation of the system 810 essentially comprises the glucose meter 828 used by a patient 812 for recording, inter alia, insulin dosage readings and measured blood glucose (“BG") levels.
- Data obtained by the glucose meter 828 is preferably transferred through appropriate communication links 814 or data modem 832 to a processor, processing station or chip 840, such as a personal computer, PDA, or cellular telephone, or via appropriate Internet portal.
- a processor, processing station or chip 840 such as a personal computer, PDA, or cellular telephone, or via appropriate Internet portal.
- data stored may be stored within the glucose meter 828 and may be directly downloaded into the personal computer 840 through an appropriate interface cable and then transmitted via the Internet to a processing location.
- glucose meter 828 and any of the computer processing modules or storage modules may be integral within a single housing or provided in separate housings.
- the glucose meter is common in the industry and includes essentially any device that can function as a BG acquisition mechanism.
- the BG meter or acquisition mechanism, device, tool or system includes various conventional methods directed towards drawing a blood sample (e.g. by fmgerprick) for each test, and a determination of the glucose level using an instrument that reads glucose concentrations by electromechanical methods.
- various methods for determining the concentration of blood analytes without drawing blood have been developed.
- U.S. Pat. No. 5,267,152 to Yang et al. (hereby incorporated by reference) describes a noninvasive technique of measuring blood glucose concentration using near-IR radiation diffuse- reflection laser spectroscopy. Similar near-IR spectrometric devices are also described in U.S. Pat. No.
- U.S. Pat. No. 5,139,023 to Stanley describes a transdermal blood glucose monitoring apparatus that relies on a permeability enhancer (e.g., a bile salt) to facilitate transdermal movement of glucose along a concentration gradient established between interstitial fluid and a receiving medium.
- a permeability enhancer e.g., a bile salt
- U.S. Pat. No. 5,279,543 to Glikfeld (hereby incorporated by reference) describes the use of iontophoresis to noninvasively sample a substance through skin into a receptacle on the skin surface. Glikfeld teaches that this sampling procedure can be coupled with a glucose-specific biosensor or glucose-specific electrodes in order to monitor blood glucose.
- International Publication No. WO 96/00110 to Tamada (hereby incorporated by reference) describes an iotophoretic apparatus for transdermal monitoring of a target substance, wherein an iotophoretic electrode is used to move an analyte into a collection reservoir and a biosensor is used to detect the target analyte present in the reservoir.
- U.S. Pat. No. 6,144,869 to Berner (hereby incorporated by reference) describes a sampling system for measuring the concentration of an analyte present.
- the BG meter or acquisition mechanism may include indwelling catheters and subcutaneous tissue fluid sampling.
- the computer, processor or PDA 840 may include the software and hardware necessary to process, analyze and interpret the self-recorded diabetes patient data in accordance with predefined flow sequences and generate an appropriate data interpretation output.
- the results of the data analysis and interpretation performed upon the stored patient data by the computer 840 may be displayed in the form of a paper report generated through a printer associated with the personal computer 840.
- the results of the data interpretation procedure may be directly displayed on a video display unit associated with the computer 840.
- the results additionally may be displayed on a digital or analog display device.
- the personal computer 840 may transfer data to a healthcare provider computer 838 through a communication network 836.
- the data transferred through communications network 836 may include the self-recorded diabetes patient data or the results of the data interpretation procedure.
- Figure 9 shows a block diagrammatic representation of an alternative embodiment having a diabetes management system that is a patient-operated apparatus 910 having a housing preferably sufficiently compact to enable apparatus 910 to be hand- held and carried by a patient.
- a strip guide for receiving a blood glucose test strip (not shown) is located on a surface of housing 916.
- Test strip receives a blood sample from the patient 912.
- the apparatus may include a microprocessor 922 and a memory 924 connected to microprocessor 922.
- Microprocessor 922 is designed to execute a computer program stored in memory 924 to perform the various calculations and control functions as discussed in greater detail above.
- a keypad 916 may be connected to microprocessor 922 through a standard keypad decoder 926.
- Display 914 may be connected to microprocessor 922 through a display driver 930. Display 914 may be digital and/or analog. Speaker 954 and a clock 956 also may be connected to microprocessor 922. Speaker 954 operates under the control of microprocessor 922 to emit audible tones alerting the patient to possible future hypoglycemic or hyperglycemic risks. Clock 956 supplies the current date and time to microprocessor 922.
- Memory 924 also stores blood glucose values of the patient 912, the insulin dose values, the insulin types, and the parameters used by the microprocessor 922 to calculate future blood glucose values, supplemental insulin doses, and carbohydrate supplements. Each blood glucose value and insulin dose value may be stored in memory 924 with a corresponding date and time.
- Memory 924 is preferably a non-volatile memory, such as an electrically erasable read only memory (EEPROM).
- Apparatus 910 may also include a blood glucose meter 928 connected to microprocessor 922. Glucose meter 928 may be designed to measure blood samples received on blood glucose test strips and to produce blood glucose values from measurements of the blood samples. As mentioned previously, such glucose meters are well known in the art.
- Glucose meter 928 is preferably of the type which produces digital values which are output directly to microprocessor 922.
- blood glucose meter 928 may be of the type which produces analog values.
- blood glucose meter 928 is connected to microprocessor 922 through an analog to digital converter (not shown).
- Apparatus 910 may further include an input/output port 934, preferably a serial port, which is connected to microprocessor 922.
- Port 934 may be connected to a modem 932 by an interface, preferably a standard RS232 interface.
- Modem 932 is for establishing a communication link between apparatus 910 and a personal computer 940 or a healthcare provider computer 938 through a communication network 936.
- Specific techniques for connecting electronic devices through connection cords are well known in the art. Another alternative example is "Bluetooth" technology communication.
- Figure 10 shows a block diagrammatic representation of an alternative embodiment having a diabetes management system that is a patient-operated apparatus 1010, similar to the apparatus as shown in Figure 9, having a housing preferably sufficiently compact to enable the apparatus 1010 to be hand-held and carried by a patient.
- a separate or detachable glucose meter or BG acquisition mechanism/module 1028 For example, a separate or detachable glucose meter or BG acquisition mechanism/module 1028.
- BG acquisition mechanism/module 1028 a separate or detachable glucose meter or BG acquisition mechanism/module 1028.
- the embodiments described herein are capable of being implemented over data communication networks such as the internet, making evaluations, estimates, and information accessible to any processor or computer at any remote location, as depicted in Figures 7-10 and/or U.S. Pat. No. 5,851,186 to Wood, of which is hereby incorporated by reference herein.
- patients located at remote locations may have the BG data transmitted to a central healthcare provider or residence, or a different remote location. It should be appreciated that any of the components/modules discussed in Figures
- 7-10 may be integrally contained within one or more housings or separated and/or duplicated in different housings.
- the various embodiments of the invention propose a data analysis computerized (or non-computerized) method and system for quantifying insulin sensitivity using episodic self-monitoring BG (SMBG) data combined with obtainable individual parameters, such as age and body mass index (BMI).
- SMBG episodic self-monitoring BG
- BMI body mass index
- the various embodiments of the invention enhance hand-held devices (e.g. PDAs or any applicable devices or systems) intended to assist diabetes management.
- the various embodiments of the invention enhance software that retrieves SMBG data.
- This software can reside on patients' personal computers, or be used via Internet portal.
- the various embodiments of the invention may evaluate the effectiveness of various treatments for diabetes (e.g. insulin or variability lowering medications, such as pramlintide and exenatide).
- diabetes e.g. insulin or variability lowering medications, such as pramlintide and exenatide.
- the various embodiments of the invention may evaluate the effectiveness of new insulin delivery devices (e.g. insulin pumps), or of future closed- loop diabetes control systems.
- new insulin delivery devices e.g. insulin pumps
- future closed- loop diabetes control systems e.g. insulin pumps
- the methods and systems of the present invention can be used separately, in combination, or in addition to previously described methods, to drive a system of messages delivered by the device to an individual with diabetes, in this case at a time proximal to a patient BG test.
- a theoretical model of self-regulation behavior asserts that such messages would be effective and would result in improved glycemic control, for example.
- insulin sensitivity (or its inverse, insulin resistance) is one of the most important for treatment of diabetes individual parameter.
- precise estimates of insulin sensitivity from widely available field data are currently not available - the estimation of insulin sensitivity requires lab-based blood testing of glucose and insulin values.
- An aspect of an embodiment of the present invention comprises of a method, computer method, system, computer system, device and computer program product for quantifying insulin sensitivity using routine episodic self-monitoring BG (SMBG) data combined with several easily obtainable individual parameters, such as age and body mass index.
- SMBG routine episodic self-monitoring BG
- the methods and systems are based on in part our previously developed theory of risk analysis of BG data; in particular on a recently reported measure of glucose variability - the Average Daily Risk Range (ADRR).
- the computation of insulin sensitivity has been validated via comparison with data for 30 patients with type 1 diabetes obtained during euglycemic clamp study performed in a hospital setting.
- the correlation between reference laboratory insulin sensitivity and its estimates from field data was >0.75.
- an aspect of the present invention further provides individual tailoring of two most important parameters of diabetes management: insulin/carbohydrate ratio and correction factor. Such adjustments could be recommended by a self-monitoring device with the accumulation of self-monitoring data.
- An aspect of an embodiment of the present invention provides, but not limited thereto, the following SMBG-related applications: > Provide accurate evaluation of one of the most important parameters of diabetes control - insulin sensitivity (or insulin resistance) - by way of a field test based on routine self-monitoring (SMBG) data; > Provide evaluation of individualized insulin/carbohydrate ratio and correction factor based on individual insulin sensitivity;
- Some non-limiting and exemplary advantages attributed with the present invention methods and systems over the existing technologies include: (i) Tracking of changes in insulin sensitivity from readily available routine self-monitoring data; (ii) Individualized assessment of insulin/carbohydrate ratio and correction factor that changes over time with the changes of a person's insulin sensitivity.
- PCT/US2008/067725 entitled “Method, System and Computer Simulation Environment for Testing of Monitoring and Control Strategies in Diabetes,” filed June 20, 2008; PCT/US2007/085588 not yet published filed November 27, 2007, entitled
- Cobelli C Measurement of Insulin Sensitivity and ⁇ - cell Function from Intravenous and Oral Glucose Tolerance Tests: Necessity of Models. Presentation at UVA
- Ferrannini E Insulin resistance versus insulin deficiency in non-insulin dependent diabetes mellitus: problems and prospects. Endocr Rev Jj): 477 -490,1998 20. Friedberg SJ, Lam YWF, Blum JJ, Gregerman RI: Insulin absoption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus. Metab Clin. 21. Flier JS: Syndromes of insulin resistance. In: Becker KL, ed. Principles and Practice of Endocrinology & Metabolism, 2nd ed. Philadelphia, Pa: JB Lippincott Company; 1995: 1245-1259 22.
- Gerich JE The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 19:491 -503,1998 23. Hanley AJG, D'Agostino R, Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM. Increased Proinsulin Levels and Decreased Acute Insulin Response Independently Predict the Incidence of Type 2 Diabetes in the Insulin Resistance Atherosclerosis Study. Diabetes 5J_:1263-1270, 2002
- any particular described or illustrated activity or element any particular sequence or such activities, any particular size, speed, material, duration, contour, dimension or frequency, or any particularly interrelationship of such elements.
- any activity can be repeated, any activity can be performed by multiple entities, and/or any element can be duplicated.
- any activity or element can be excluded, the sequence of activities can vary, and/or the interrelationship of elements can vary. It should be appreciated that aspects of the present invention may have a variety of sizes, contours, shapes, compositions and materials as desired or required.
- any activity or element can be excluded, the sequence of activities can vary, and/or the interrelationship of elements can vary. Unless clearly specified to the contrary, there is no requirement for any particular described or illustrated activity or element, any particular sequence or such activities, any particular size, speed, material, dimension or frequency, or any particularly interrelationship of such elements. Accordingly, the descriptions and drawings are to be regarded as illustrative in nature, and not as restrictive. Moreover, when any number or range is described herein, unless clearly stated otherwise, that number or range is approximate. When any range is described herein, unless clearly stated otherwise, that range includes all values therein and all sub ranges therein.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Databases & Information Systems (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880107765A CN101801262A (en) | 2007-07-09 | 2008-07-08 | Diabetes insulin sensitivity, carbohydrate ratio, correction factors data self-monitoring product |
EP08781497A EP2164387A4 (en) | 2007-07-09 | 2008-07-08 | Diabetes insulin sensitivity, carbohydrate ratio, correction factors data self-monitoring product |
BRPI0813708-0A2A BRPI0813708A2 (en) | 2007-07-09 | 2008-07-08 | COMPUTER PROGRAM METHOD, SYSTEM AND PRODUCT FOR INSULIN SENSITIVITY ASSESSMENT, INSULIN / CARBOHYDRATE COEFFICIENT, AND DAILY INSULIN CORRECTION FACTORS FROM SELF-MONITORING DATA |
CA002691826A CA2691826A1 (en) | 2007-07-09 | 2008-07-08 | Method, system and computer program product for evaluation of insulin sensitivity, insulin/carbohydrate ratio, and insulin correction factors in diabetes from self-monitoring data |
US12/665,149 US20100198520A1 (en) | 2007-07-09 | 2008-07-08 | Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data |
JP2010516197A JP5501963B2 (en) | 2007-07-09 | 2008-07-08 | System and computer program product for assessing insulin sensitivity, insulin / carbohydrate ratio, and insulin correction function in diabetes from self-monitoring data |
US16/126,879 US20190019571A1 (en) | 2007-07-09 | 2018-09-10 | Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95876707P | 2007-07-09 | 2007-07-09 | |
US60/958,767 | 2007-07-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/665,149 A-371-Of-International US20100198520A1 (en) | 2007-07-09 | 2008-07-08 | Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data |
US16/126,879 Continuation US20190019571A1 (en) | 2007-07-09 | 2018-09-10 | Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009009528A2 true WO2009009528A2 (en) | 2009-01-15 |
WO2009009528A3 WO2009009528A3 (en) | 2009-03-05 |
Family
ID=40229444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/069416 WO2009009528A2 (en) | 2007-07-09 | 2008-07-08 | Diabetes insulin sensitivity, carbohydrate ratio, correction factors data self-monitoring product |
Country Status (8)
Country | Link |
---|---|
US (2) | US20100198520A1 (en) |
EP (1) | EP2164387A4 (en) |
JP (1) | JP5501963B2 (en) |
CN (1) | CN101801262A (en) |
BR (1) | BRPI0813708A2 (en) |
CA (1) | CA2691826A1 (en) |
RU (1) | RU2010104254A (en) |
WO (1) | WO2009009528A2 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011028925A1 (en) * | 2009-09-02 | 2011-03-10 | University Of Virginia Patent Foundation | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (smbg) data |
GB2493712A (en) * | 2011-08-12 | 2013-02-20 | Gene Onyx Ltd | Controlling an insulin pump using a gain factor |
CN103268414A (en) * | 2013-05-20 | 2013-08-28 | 吉林市同益科技开发有限公司 | Phenylketonuria managing method and system |
US8755938B2 (en) | 2011-05-13 | 2014-06-17 | Roche Diagnostics Operations, Inc. | Systems and methods for handling unacceptable values in structured collection protocols |
US8766803B2 (en) | 2011-05-13 | 2014-07-01 | Roche Diagnostics Operations, Inc. | Dynamic data collection |
US8784364B2 (en) | 2008-09-15 | 2014-07-22 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
US8849458B2 (en) | 2008-12-23 | 2014-09-30 | Roche Diagnostics Operations, Inc. | Collection device with selective display of test results, method and computer program product thereof |
US9117015B2 (en) | 2008-12-23 | 2015-08-25 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US10216767B2 (en) | 2008-12-23 | 2019-02-26 | Roche Diabetes Care, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US10368745B2 (en) | 2008-12-23 | 2019-08-06 | Roche Diabetes Care Inc | Systems and methods for optimizing insulin dosage |
US10420489B2 (en) | 2009-05-29 | 2019-09-24 | University Of Virginia Patent Foundation | System coordinator and modular architecture for open-loop and closed-loop control of diabetes |
US10437962B2 (en) | 2008-12-23 | 2019-10-08 | Roche Diabetes Care Inc | Status reporting of a structured collection procedure |
US10456036B2 (en) | 2008-12-23 | 2019-10-29 | Roche Diabetes Care, Inc. | Structured tailoring |
US10463789B2 (en) | 2015-09-02 | 2019-11-05 | University Of Virginia Patent Foundation | System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users |
US10522247B2 (en) | 2010-12-29 | 2019-12-31 | Roche Diabetes Care, Inc. | Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels |
EP3593711A1 (en) | 2010-03-26 | 2020-01-15 | The University of Virginia Patent Foundation | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes |
US10565170B2 (en) | 2008-12-23 | 2020-02-18 | Roche Diabetes Care, Inc. | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
US10881334B2 (en) | 2014-08-14 | 2021-01-05 | University Of Virginia Patent Foundation | Accuracy continuous glucose monitoring method, system, and device |
EP3799073A1 (en) | 2011-08-26 | 2021-03-31 | The University of Virginia Patent Foundation | Method, system and computer readable medium for adaptive advisory control of diabetes |
US11311665B2 (en) | 2015-06-09 | 2022-04-26 | University Of Virginia Patent Foundation | Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
US20080172026A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having a suspension bolus |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
JP5677322B2 (en) * | 2009-02-04 | 2015-02-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Medical system and method for providing information for blood glucose control |
AU2010278894B2 (en) | 2009-07-30 | 2014-01-30 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN102596307B (en) * | 2009-09-01 | 2015-09-09 | 弗吉尼亚大学专利基金会 | Utilize nominal open loop characteristic in diabetes, carry out system, the method and computer program product of insulin feed adjustment (AID) |
US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
US8615366B2 (en) * | 2010-10-15 | 2013-12-24 | Roche Diagnostics Operations, Inc. | Handheld diabetes management device with bolus calculator |
US20120197621A1 (en) * | 2011-01-31 | 2012-08-02 | Fujitsu Limited | Diagnosing Insulin Resistance |
US9486172B2 (en) * | 2011-10-26 | 2016-11-08 | Università Degli Studi Di Padova | Estimation of insulin sensitivity from CGM and subcutaneous insulin delivery in type 1 diabetes |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9990581B2 (en) | 2012-07-11 | 2018-06-05 | Roche Diabetes Care, Inc. | Insulin dosage assessment and recommendation system |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9242043B2 (en) | 2013-03-15 | 2016-01-26 | Tandem Diabetes Care, Inc. | Field update of an ambulatory infusion pump system |
US9492608B2 (en) | 2013-03-15 | 2016-11-15 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
WO2015100439A1 (en) | 2013-12-26 | 2015-07-02 | Tandem Diabetes Care, Inc. | Integration of infusion pump with remote electronic device |
EP3087548A4 (en) | 2013-12-26 | 2017-09-13 | Tandem Diabetes Care, Inc. | Safety processor for wireless control of a drug delivery device |
JP6401297B2 (en) * | 2014-12-25 | 2018-10-10 | 株式会社日立製作所 | Insulin secretion capacity analysis apparatus, insulin secretion capacity analysis system including the apparatus, and insulin secretion capacity analysis method |
US20180130551A1 (en) * | 2015-05-13 | 2018-05-10 | Ascensia Diabetes Care Holdings Ag | Blood glucose management device for calculating bolus insulin |
CN108024745B (en) * | 2015-09-25 | 2021-09-07 | 三线性生物公司 | Health care monitoring system and biosensor |
WO2017061943A1 (en) * | 2015-10-09 | 2017-04-13 | Dianovator Ab | Medical arrangements and a method for determining parameters related to insulin therapy, predicting glucose values and for providing insulin dosing recommendations |
US9974903B1 (en) | 2016-05-02 | 2018-05-22 | Dexcom, Inc. | System and method for providing alerts optimized for a user |
US10332632B2 (en) * | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range failsafes |
EP3500960A1 (en) | 2016-08-17 | 2019-06-26 | Novo Nordisk A/S | Systems and methods for optimization of bolus timing relative to meal events |
CA3075124C (en) | 2016-09-09 | 2023-05-02 | Dexcom, Inc. | Systems and methods for cgm-based bolus calculator for display and for provision to medicament delivery devices |
CN106730153B (en) * | 2016-12-02 | 2019-10-01 | 杜少良 | A kind of modularization Regulation of blood glucose system |
US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
CN112041936A (en) | 2017-12-12 | 2020-12-04 | 比格福特生物医学有限公司 | Treatment assistance information and/or tracking devices and related methods and systems |
US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
US11083852B2 (en) | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
US11464459B2 (en) * | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
CA3089642A1 (en) | 2018-02-09 | 2019-08-15 | Dexcom, Inc. | System and method for decision support |
EP3776801A4 (en) | 2018-04-10 | 2021-12-22 | Tandem Diabetes Care, Inc. | System and method for inductively charging a medical device |
FR3081316B1 (en) | 2018-05-22 | 2022-12-09 | Commissariat Energie Atomique | AUTOMATED PATIENT GLYCEMIA MONITORING SYSTEM |
FR3081315B1 (en) | 2018-05-22 | 2022-12-02 | Commissariat Energie Atomique | AUTOMATED PATIENT GLYCEMIA MONITORING SYSTEM |
CN109192318A (en) * | 2018-07-11 | 2019-01-11 | 辽宁石油化工大学 | The foundation and Laplace for describing the simplification SIS model of infectious disease transmission process are analyzed |
CN114760918A (en) | 2019-07-16 | 2022-07-15 | 贝塔仿生公司 | Blood sugar control system |
US11957876B2 (en) | 2019-07-16 | 2024-04-16 | Beta Bionics, Inc. | Glucose control system with automated backup therapy protocol generation |
CA3146872A1 (en) | 2019-07-16 | 2021-01-21 | Beta Bionics, Inc. | Blood glucose control system |
US20230266340A1 (en) * | 2022-02-24 | 2023-08-24 | Fernando García Sada | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7404796B2 (en) * | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
US7137951B2 (en) * | 2002-10-23 | 2006-11-21 | Joseph Pilarski | Method of food and insulin dose management for a diabetic subject |
US7291107B2 (en) * | 2004-08-26 | 2007-11-06 | Roche Diagnostics Operations, Inc. | Insulin bolus recommendation system |
EP1988821B1 (en) * | 2006-01-05 | 2023-06-28 | University Of Virginia Patent Foundation | Method, system and computer program product for evaluation of blood glucose variability in diabetes from self-monitoring data |
-
2008
- 2008-07-08 BR BRPI0813708-0A2A patent/BRPI0813708A2/en not_active IP Right Cessation
- 2008-07-08 EP EP08781497A patent/EP2164387A4/en not_active Withdrawn
- 2008-07-08 US US12/665,149 patent/US20100198520A1/en not_active Abandoned
- 2008-07-08 WO PCT/US2008/069416 patent/WO2009009528A2/en active Application Filing
- 2008-07-08 JP JP2010516197A patent/JP5501963B2/en active Active
- 2008-07-08 CN CN200880107765A patent/CN101801262A/en active Pending
- 2008-07-08 CA CA002691826A patent/CA2691826A1/en not_active Abandoned
- 2008-07-08 RU RU2010104254/14A patent/RU2010104254A/en not_active Application Discontinuation
-
2018
- 2018-09-10 US US16/126,879 patent/US20190019571A1/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP2164387A4 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11395877B2 (en) | 2006-02-09 | 2022-07-26 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
US10010669B2 (en) | 2006-02-09 | 2018-07-03 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
US8784364B2 (en) | 2008-09-15 | 2014-07-22 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
US11707567B2 (en) | 2008-09-15 | 2023-07-25 | Deka Products Limited Partnership | System and methods for fluid delivery |
US10437962B2 (en) | 2008-12-23 | 2019-10-08 | Roche Diabetes Care Inc | Status reporting of a structured collection procedure |
US10733154B2 (en) | 2008-12-23 | 2020-08-04 | Roche Diabetes Care Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US11382507B2 (en) | 2008-12-23 | 2022-07-12 | Roche Diabetes Care, Inc. | Structured tailoring |
US11350822B2 (en) | 2008-12-23 | 2022-06-07 | Roche Diabetes Care, Inc. | Status reporting of a structured collection procedure |
US8849458B2 (en) | 2008-12-23 | 2014-09-30 | Roche Diagnostics Operations, Inc. | Collection device with selective display of test results, method and computer program product thereof |
US9117015B2 (en) | 2008-12-23 | 2015-08-25 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US11327931B2 (en) | 2008-12-23 | 2022-05-10 | Roche Diabetes Care, Inc. | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
US10565170B2 (en) | 2008-12-23 | 2020-02-18 | Roche Diabetes Care, Inc. | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
US10216767B2 (en) | 2008-12-23 | 2019-02-26 | Roche Diabetes Care, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US10368745B2 (en) | 2008-12-23 | 2019-08-06 | Roche Diabetes Care Inc | Systems and methods for optimizing insulin dosage |
US11907180B2 (en) | 2008-12-23 | 2024-02-20 | Roche Diabetes Care, Inc. | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
US10456036B2 (en) | 2008-12-23 | 2019-10-29 | Roche Diabetes Care, Inc. | Structured tailoring |
US10420489B2 (en) | 2009-05-29 | 2019-09-24 | University Of Virginia Patent Foundation | System coordinator and modular architecture for open-loop and closed-loop control of diabetes |
US10431342B2 (en) | 2009-09-02 | 2019-10-01 | University Of Virginia Patent Foundation | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (SMBG) data |
CN102770761A (en) * | 2009-09-02 | 2012-11-07 | 弗吉尼亚大学专利基金会 | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (SMBG) data |
WO2011028925A1 (en) * | 2009-09-02 | 2011-03-10 | University Of Virginia Patent Foundation | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (smbg) data |
EP3841968A1 (en) | 2010-03-26 | 2021-06-30 | The University of Virginia Patent Foundation | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes |
EP3593711A1 (en) | 2010-03-26 | 2020-01-15 | The University of Virginia Patent Foundation | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes |
EP4183326A1 (en) | 2010-03-26 | 2023-05-24 | University Of Virginia Patent Foundation | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes |
US10522247B2 (en) | 2010-12-29 | 2019-12-31 | Roche Diabetes Care, Inc. | Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels |
US8755938B2 (en) | 2011-05-13 | 2014-06-17 | Roche Diagnostics Operations, Inc. | Systems and methods for handling unacceptable values in structured collection protocols |
US8766803B2 (en) | 2011-05-13 | 2014-07-01 | Roche Diagnostics Operations, Inc. | Dynamic data collection |
US9283323B2 (en) | 2011-08-12 | 2016-03-15 | Gene Onyx Limited | Insulin pump |
GB2493712B (en) * | 2011-08-12 | 2014-07-02 | Gene Onyx Ltd | Insulin pump |
GB2493712A (en) * | 2011-08-12 | 2013-02-20 | Gene Onyx Ltd | Controlling an insulin pump using a gain factor |
EP3799073A1 (en) | 2011-08-26 | 2021-03-31 | The University of Virginia Patent Foundation | Method, system and computer readable medium for adaptive advisory control of diabetes |
CN103268414A (en) * | 2013-05-20 | 2013-08-28 | 吉林市同益科技开发有限公司 | Phenylketonuria managing method and system |
US10881334B2 (en) | 2014-08-14 | 2021-01-05 | University Of Virginia Patent Foundation | Accuracy continuous glucose monitoring method, system, and device |
US11311665B2 (en) | 2015-06-09 | 2022-04-26 | University Of Virginia Patent Foundation | Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking |
US11951278B2 (en) | 2015-06-09 | 2024-04-09 | University Of Virginia Patent Foundation | Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking |
US20200023126A1 (en) * | 2015-09-02 | 2020-01-23 | University Of Virginia Patent Foundation | System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users |
US10463789B2 (en) | 2015-09-02 | 2019-11-05 | University Of Virginia Patent Foundation | System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users |
Also Published As
Publication number | Publication date |
---|---|
US20100198520A1 (en) | 2010-08-05 |
JP2010533038A (en) | 2010-10-21 |
CA2691826A1 (en) | 2009-01-15 |
RU2010104254A (en) | 2011-08-20 |
CN101801262A (en) | 2010-08-11 |
BRPI0813708A2 (en) | 2014-12-30 |
US20190019571A1 (en) | 2019-01-17 |
EP2164387A2 (en) | 2010-03-24 |
EP2164387A4 (en) | 2011-09-07 |
JP5501963B2 (en) | 2014-05-28 |
WO2009009528A3 (en) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190019571A1 (en) | Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data | |
US20210361867A1 (en) | Integrated closed-loop medication delivery with error model and safety check | |
US11751779B2 (en) | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery | |
US11355238B2 (en) | Method, system and computer program product for evaluation of blood glucose variability in diabetes from self-monitoring data | |
EP2369980B1 (en) | METHOD and SYSTEM FOR TRACKING OF BLOOD GLUCOSE VARIABILITY IN DIABETES | |
CA2615575C (en) | Systems, methods and computer program products for recognition of patterns of hyperglycemia in a user | |
US20050234311A1 (en) | Diagnostic support system for diabetes and storage medium | |
WO2010054777A9 (en) | System and method for determining optimal insulin profiles | |
JP2003528330A (en) | Method, system, and computer program product for evaluating blood glucose control of diabetes from self-monitoring data | |
Little et al. | Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial) | |
Unnikrishnan et al. | Suggested Protocols for Self-Monitoring of Blood Glucose in India | |
Chen | Impact of Continuous Glucose Monitoring System on Model Based Glucose Control | |
Qu et al. | Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type1 and Patients with Type2 Diabetes in China |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880107765.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08781497 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12665149 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2691826 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2008781497 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 80/KOLNP/2010 Country of ref document: IN Ref document number: 2008781497 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010516197 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010104254 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0813708 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100111 |